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Abstract 
Freshly aspirated human granulosa ceHs from pre-ovulatory follicles and granulosa ceHs luteinized in culture possess the neural ceH adhesion 
molecule (NCAM) of approximate molecu1ar mass of 140,000 and NCAM mRNA as confirmed by Sl-nuclease protection assays and RT-PCR. 
Moreover, in the process of luteinization the NCAM isoform pattern is modified. Isoforms containing an insert of 10 amino acids (termed VASE) 
in the extraceHular domain of NCAM were supplemented by alternatively spliced isoforms without this insert. NCAM immunoreactivity, at light 
and electron microscope levels, was associated with the ceH membrane of most granulosa ceHs which formed clusters. During time in culture an 
increasing subpopulation of granulosa ceHs, devoid of NCAM immunoreactivity, spread out and formed monolayers. This differential expression 
and the alternative splicing of NCAM during luteinization of granulosa ceHs raise the possibility that NCAM could be involved in folliculogenesis 
and the formation of the corpus luteum in the human. 
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1. Introduction 
The neural cell adhesion moleeule (NCAM) glycopro-
tein family consists of three major members with 
molecular masses of 120, 140 and 180 kDa, which are 
generated from a single gene by alternative splicing (cf. 
[1,2]). At least 20 major exons code for these ditTerent 
isoforms [2,3]. In addition, further small exons can give 
rise to additional NCAM isoforms. Between exons 12 
and 13, four additional independent alternatively spliced 
exons of 3-48 bp [3-6] and at the exon 7/8 splice junction 
a 30 bp exon (termed VASE) [5,7] were discovered. The 
alternatively spliced exon VASE is close to the NCAM 
domain that mediates cell-cell adhesion [8]. The biologi-
cal relevance of VASE expression still remains obscure, 
however, in the nervous system, VASE has been shown 
to down-regulate the neurite growth-promoting etTect of 
NCAM [9]. NCAM mRNAs containing VASE were also 
present in rodent endocrine tissues and cells [10]. 
NCAMs were first found in the nervous system, but 
subsequently were also found in polypeptide hormone-
and steroid-producing endocrine cells [10--15]. NCAMs 
allow the formation of cell clusters by auto-adhesion of 
neighboring NCAM-bearing cells. We have previously 
described the presence of NCAM-140 and NCAM 
mRNA in the rat ovary [14]. We found that NCAM was 
most abundant in granulosa cells and luteal cells. These 
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results were confirmed by another study performed in 
the mouse [16]. Within the granulosa, forming large fol-
licles of the rat, we noticed [14] a marked ditTerence in 
the degree of NCAM immunoreactivity: the cells lining 
the follicular antrum showed stronger immunoreactivity 
than the mural granulosa cells. Moreover, follicular fluid 
stained with a NCAM antiserum. We have therefore 
proposed a role for NCAM in the dynamic processes of 
folliculogenesis, namely in the segregation of granulosa 
cells. We also suspected involvement of NCAM in the 
formation of the corpus luteum, which depends on the 
concomitant development of its vasculature. The last 
assumption is based on arecent study in the bovine 
species, in which we showed that subtypes of corpus 
luteum-derived microvasculature endothelial cells ex-
press NCAM-140 [17], extending our idea of an involve-
ment of NCAM in the formation of the corpus luteum. 
Thus, accumulating evidence for a functional signifi-
cance of NCAM in the ovary led us to examine whether 
ovarian NCAM expression also occurs in the human 
ovary. Because of the possible clinical relevance of gran-
ulosa cells' expression of NCAM during folliculogenesis 
and luteinization, in the present study we have examined 
NCAM expression by aspirated human granulosa cells 
and by cultured human granulosa-lutein cells. 
2. Materials and methods 
2.1. Culture of human granulosa-Iutein cells and lung tumor cell lines 
Granulosa ceHs were cultured in DMEM:Ham's F12 medium (1: 1; 
vIv; Sigma, Munich, Germany) [18-20]. We found that coating of cul-
ture dishes with laminin (Sigma, Munich, Germany) supported the 
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adherence of the cells during immunocytochemistry, while other differ-
ences were not seen. Therefore cells grown on both laminin-coated and 
non-coated dishes were examined in the present study. The human 
small cell carcinoma cell line, SCLC H69 (Deutsches Krebs-
forschungszentrum (DKFZ), Heidelberg, Germany) was grown under 
serum-free conditions (thus termed H69-) in RPMI 1640 medium (Bio-
chrom Beteiligungs GmbH, Berlin, Germany) supplemented with 5 
,ug/ml bovine insulin, 10 ,ug/ml human transferrin, 30 nM sodium selen-
ite (Sigma) and 2 mM L-glutamine. The human adenocarcinoma cell 
line, A549 (DKFZ), was grown in RPMI 1640 medium containing 10% 
FCS (Biochrom Beteiligungs GmbH). 
2.2. Cloning of human NCAM cDNA 
Total RNA was isolated from human SCLC H69-, human 
adenocarcinoma cells A549, as well as from freshly aspirated human 
granulosa and cultured granulosa-Iutein cells, as described [21]. For 
cDNA synthesis and its amplification by the polymerase chain reaction 
(PCR) the primers E7s (5' ACTCTTACCTGTGAAGCCTC 3', 'sense') 
and E13a (5' CATCTGCCCTTCAAGCTTAG 3', 'antisense', with the 
exception of the point mutation urlderlined, which introduces a Hindill 
restriction site) were used. 
Synthesis of cDNA and PCR amplification modified after [22] was 
carried out as described by [10] with I ,ug total RNA extracted from 
the SCLC H69- cell line using 50 pmol of each primer in a DNA 
Thermal Cycler 480 (perkin-Elmer; Applied Biosystems Weiterstadt, 
Germany). PCR amplified cDNA was separated on a 2% agarose gel. 
The DNA fragment (exon 7-13) was eluted and cloned into the SmaI 
site of Bluescribe [Mln vector (Stratagene, La Jolla, CA) after phos-
phorylation with T 4 polynucleotide kinase and repair synthesis ('fill-in') 
with Klenow enzyme (both enzymes: AGS, Angewandte Gentechnolo-
gie Systeme) using standard methods [23]. This clone containing the 884 
bp human NCAM cDNA fragment is referred to as 6hNCAM. DNA 
was sequenced by the desoxynucleotide chain termination method [24] 
using the sequencing kit from Pharmacia (Pharmacia, Freiburg, Ger-
many). 
2.3. Synthesis of cRNA-probe and S1 nuc1ease protection assay 
The cDNA clone 6hNCAM was used as a template for cRNA synthe-
sis. Synthesis of 32P-Iabelled cRNA (specific activity: 3.9 x 107 cpm/f.lg) 
for SI nuclease protection assay (SI-NPA) was carried out according 
to the T3-polymerase protocol of Promega Biotec (Madison, Wiscon-
sin, USA) using 20 ,uCi of [a_32p]UTP (specific activity: 15 TBq/mmol) 
and 2 ,ug of 6hNCAM cut with EcoRI (using the internal EcoRI site, 
as well as the EcoRI site in the polylinker sequence of the vector). The 
resulting cRNA probe contained 354 nt ofhuman NCAM (exons lO-
B) corresponding to the published sequence (positions 1576-1933 plus 
an additional triplet AAG between exon 12 and 13) ofhuman NCAM 
[25] and 45 nt of vector sequences. 
SI-NPA with labelIed cRNA probe was carried out as described 
previously [10,26]. 
2.4. Analysis of the alternative exon VASE by RT-PCR 
cDNA synthesis from RNA isolated from granulosa cells harvested 
after different time periods in culture was carried out with 20 ,ug ex-
tracted total RNA. A random-primed reverse transcription (RT) was 
carried out for 30 min at 37°C in a 50,u1 reaction mix according to the 
manufacturers protocol (GIBCOIBRL, Eggenstein, Germany) using 
200 U M-MLV-reverse transcriptase, 2,u1 of 10 x hexanucleotide mix-
ture (Boehringer-Mannheim, Mannheim, Germany), and 29 U RNA 
guard (Pharmacia, Freiburg, Germany). 
PCR amplification was performed with a 2 ,ul aliquot immediately 
after inactivation of reverse transcriptase in a 50 ,ul reaction mix con-
taining 0.5 U of Taq DNA polymerase according to the protocol of 
AGS (Angewandte Gentechnologie Systeme, Heidelberg, Germany), 
using 2 mM dATP, dGTP, dCTP, dTTP ('cold PCR', Le. unlabelled), 
or I mM dCTP and 5,uCi [a_p32]dCTP ('hot PCR', i.e. radioloabelled), 
and 20 pmol of each primer E7s (see above) and E9a (5' ACCTCA-
CAGGTGATGTTCAC 3') 'antisense' (see also [10]). 
2.5. lmmunocytochemistryand Western blotting 
The immunocytochemicallocalization of NCAM [27] on cells at day 
land 5 after isolation was examined with a well-characterized NCAM 
antiserum directed against the N-terminal end of NCAM (I: 500-
I: 1,000; generous gift from Dr. G. Rougon, Marseille) and 
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a commercial NCAM antiserum (I: 100-1 : 500; Serva, Heidelberg, 
Germany). The details of the immunocytochemical techniques have 
been described [14,17]. The avidin-biotin (ABC -method was performed 
(reagents included a I : 500 dilution of a goat anti-rabbit IgG (Carnon, 
Wiesbaden, Germany) and an ABC kit (Carnon» after paraformalde-
hyde fixation ofthe cells (4% in 0.01 M phosphate-buffered saline, PBS, 
pH 7.3). Controls, performed by (i) omitting the first antisera, and (ii) 
incubation with normal rabbit serum instead of the specific antisera, 
were negative. 
To obtain further information on NCAM localization, immunocyto-
chemistry at the electron microscope level was performed. After im-
munostaining (see above), cells were immediately post-fixed with 5% 
glutaraldehyde in 0.05 M cacodylate buffer (pH 7.4) for 1 h. Cells were 
treated with 1% OS04 for 30 min and then embedded into Epon. Thin 
sections were cut, most were viewed unstained but some were stained 
with uranyl acetate for 15 s, lead citrate for 1 min and were then 
examined with a Zeiss EM 10 transmission electron microscope. 
As described previously [14,17] medium and cells (which were 
scratched from the culture plates) were centrifuged and the pellets were 
transferred into 62.5 mM Tris-HCI (pH 6.8) containing 10% sucrose 
and 2% sodium dodecyl sulfate. After sonication and heating (100°C 
for 5 min), sampies (15 ,ug of protein per lane) were subjected to 
electrophoretic separation on 7.5% SDS-polyacrylamide gels. The gels 
were biotted onto nitrocellulose membranes and probed with the same 
NCAM antisera as used for immunocytochemistry (1: 500 dilution of 
antiserum donated by Dr. Rougon; I: 100 dilution ofServa antiserum). 
3. Results 
During the first 2 days of culture NCAM im-
munoreactivity was found to be associated with the cell 
membrane of cells sticking closely together and forming 
clusters (Fig. la,b). Cells spreading out and forming 
monolayers, a process increasing with time in culture, 
exhibited low or no NCAM immunoreactivity. However, 
with increasing length of culture period, strong NCAM 
immunoreactivity was present on cells segregating from 
the (NCAM-immunonegative) monolayer (Fig. lc). The 
faint cytoplasmic staining of attached cells in Fig. la and 
c was not observed in controls and thus may represent 
an intracellular pool of NCAM. While NCAM was not 
readily detectable in immunoblots of freshly aspirated 
granulosa cells, NCAM of approximately 140,000 mo-
lecular mass was found in cultured granulosa-Iutein cells 
on culture day 5 (Fig. 2), if adherent cells and floating 
cells (see below) were sampled together. 
Further evidence for the presence ofNCAM in human 
granulosa cells was obtained by SI nuclease assays. The 
large differences in sequence between rodent NCAM and 
human NCAM excluded the use of probes for rodent 
NCAM for SI nuclease analyses for the positive identifi-
cation of NCAM mRNA in human granulosa cells. 
Therefore, we isolated mRNA from human small cell 
carcinoma cells, synthesized cDNA, amplified it by PCR, 
and cloned it into a suitable vector (see Fig. 3 and section 
2). Sequence analysis revealed that the clone (6hNCAM) 
obtained differs in sequence from the published human 
NCAM derived from a human neuroblastoma cDNA 
library [25] at two positions (Fig. 3). At the exonlO/exon 
11 splice junction at position 1589, aG is replaced by a 
C. Whether this transversion at position 1589 in clone 
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Fig. I. NCAM-immunoreactivity on cultured granulosa-Iutein cells. (a) 
NCAM immunoreactivity (arrows) was detected in adhering cells which 
form clusters, but cells spreading out on the plastic surface (marked 
with an asterisk) were unstained (culture day I; antiserum from Serva, 
Heide1berg was diluted I: I 00; bar = 40 pm). (b) At the electron micro-
scope level NCAM immunoreactivity was associated with the cell mem-
brane (arrows; culture day I; antiserum from Dr. G. Rougon was 
diluted 1:500; bar = I pm). (c) After 5 days in culture, granulosa-Iutein 
cells formed monolayers. The adhering granulosa-Iutein cells had no 
detectabe NCAM immunoreactivity. However, NCAM-immunoreac-
tive cells (arrows) rounding up and segregating from the monolayer 
were found (antiserum from Dr. G. Rougon, I : 500; bar = 40 pm). 
6hNCAM is due to a PCR- or cloning artifact remains 
unclear. At position 1720, G is replaced by T, a transi-
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tion having no effect on the amino acid composition. 
Since T at position 1720 was also found in the human 
muscle sequence [28] it can be concluded that it may be 
characteristic for human muscle and small celllung can-
cer, whereas the G nucleotide at position 1720 [25] may 
be characteristic for human neural tissue. Furthermore 
the AAG trinucleotide at the exon 12/exon 13 splice 
junction observed in the sequence of human brain 
NCAM [25] is not present in clone 6hNCAM. These 
small differences in sequence do not exclude the use of 
the probes for protection analyses, since the enzym SI 
nuclease does not recognize up to three consecutive mis-
matches [6]. 
The structure of the cDNA, the cRNA probe for SI 
nuclease assays and the protected cRNA fragment indi-
cating co-linearity with the NCAM cRNA probe are 
shown in Fig. 3. Results of SI nuclease assays showed 
that freshly aspirated human granulosa cells from pre-
ovulatory follicles possess mRNA coding for NCAM 
(Fig. 4). NCAM mRNA was also present in these cells 
during culture, when they underwent luteinization. 
NCAM mRNA was identified among RNA isolated 
from human small lung cell carcinoma cells (H69-), 
which were used as a positive control, but was absent in 
the human adenocarcinoma cellline A549 (negative con-
trol) [29]. 
The microsplicing event of the alternatively spliced 
extra exon, VASE, was analysed by PCR analysis using 
oligonucleotide primers downstream and upstream of 
the exon 7/8 splice junction after cDNA synthesis and 
PCR amplification (Fig. 5). As indicated by the band of 
337 bp, freshly isolated human granulosa cells and cells 
after 1 day in culture express mainly NCAM mRNAs 
with VASE. Non-VASE mRNAs (307 bp band), aug-
mented during the culturing period (2 days in culture) 
until similar amounts ofNCAM with and without VASE 
were detected after 4 days in culture. 
180 
140 
120-
1 2 
Fig. 2. Western blot analyses of NCAM in granulosa cells. NCAM of 
approximately 140,000 molecular mass was found in cultured gran-
ulosa-Iutein cells on culture day 5 (Iane 2). Human olfactory bulb 
(Iane I) was used as a positive control containing NCAM isoforms of 
120,000, 140,000 and 180,000 Da. (Antiserum, diluted I: 500, was ob-
tained from Dr. Rougon.) 
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Fig. 3. Scheme of the sequenced human NCAM cDNA, the NCAM cRNA probe used for SI nuc1ease protection assay and its protected fragment. 
The 887 bp hNCAM cDNA fragment amplified by PCR between exons 7 and 13 cloned into Bluescribe M13(-) vector is shown on the top. The 
T3 promoter, the EcoRI restriction site and the vector sequences are indicated. During sequencing we observed a transversion (G~C; see asterisk 
at position 1589) at the exon 1O/exon 11 splice junction, which would change the amino acid sequence from an alanine to a proHne. We found, in 
addition, a transition (G~T; see asterisk at position 1720), which is also present in human musc1e (see section 4). Note that the sequenced clone 
contains no AAG triplet at the exon 12113 junction, which was present in the published sequence ofhuman NCAM derived from a neuroblastoma 
cDNA library [25). The cRNA probe (399 nt) synthesized from cDNA 6hNCAM M13(-) spans the NCAM sequence between the internal EcoRI 
restriction site in exon 10 and exon 13. The 354 nt RNA fragment (nuc1eotide position l57~1933), protected from SI nuc1ease hydrolysis, is shown 
at the bottom. 
4. Discussion 
The principal finding of the present study is that 
NCAM and its mRNA are present in human granulosa 
cells and in granulosa-lutein cells in culture. In addition, 
we observed that during differentiation in culture, cells 
lose NCAM during the process of adhesion and spread-
ing. However, cells express NCAM again when they seg-
regate from the monolayers. Differential alternative 
splicing occured during culture. NCAM mRNAs with-
out the additional exon, VASE, were generated in addi-
tion to NCAM mRNAs including VASE, which were 
present thoughout the culturing period. 
We have previously reported the expression of the 
neural cell adhesion molecule, NCAM-140, in follicles 
and in the corpus luteum of the rat ovary [14]. These 
results were confirmed by a study in the mouse ovary 
[16]. In our previous study we speculated that NCAM 
could be a factor involved in the formation of the follicu-
lar antrum and of the corpus luteum [14]. The present 
study largely extends our previous work and focuses on 
human granulosa and cultured granulosa-lutein cells. 
We present evidence that the expression of NCAM 
changes: while early after seeding granulosa-lutein cells 
adhering to each other showed NCAM immunoreactiv-
ity, NCAM immunoreactivity vanished with time in cul-
ture in cells spreading out and was not detectable on the 
cells forming monolayers. However, strong NCAM im-
munoreactivity was present on cells segregating from the 
monolayers, floating in the medium, or only loosely ad-
herent cells. Many ofthe last mentioned cells presumably 
were washed off during the immunocytochemical proce-
dure and therefore might have escaped observation. For 
most Western blots both adherent and floating cellS were 
used, allowing the identification ofNCAM with a molec-
ular weight of 140 kDa in granulosa-lutein cells in cul-
ture. The behavior of granulosa-lutein cells in losing 
NCAM after spreading is reminiscent of the NCAM 
down-regulation observed in a NCAM-expressing tumor 
line: a subpopulation of a human small cell lung cancer 
line down-regulated its NCAM and became adherent to 
the culture dish [30]. 
In the present study we have used a human small cell 
lung cancer line as a positive control for human NCAM 
mRNA. It is well documented that these tumor cells 
express NCAM [29,31-33]. The use of a cDNA probe for 
human NCAM obtained from this celliine became essen-
tial for the positive identification of human NCAM 
mRNA in human granulosa cells, because the sequences 
527 -
404 - --- 399 nt 
.. 354 nt 
309 -
'---------' 
123456 
Fig. 4. SI nuclease protection analysis of extracted RNA of human 
granulosa ceHs and human lung tumor ceH lines. Human NCAM 
mRNA is present in freshly aspirated granulosa ceHs (lane 5), in gran-
ulosa ceHs cultured for 5 days (lane 6), in a human small cell carcinoma 
ceH line (H69-) (lane 3), but not in a human adenocarcinoma cell line 
(A549) (lane 4). As a size marker, Hpall-digested pBR322 was used and 
the fragment sizes are indicated at the left side. In lane 1 the probe 
containing flanking vector sequences is shown. The thin arrow depicts 
the undigested probe of 399 nt, whereas the bold arrow points to the 
protected cRNA fragment of 354 nt. Lane 2 = tRNA control. 
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Fig. 5. PCR analysis of the expression of the alternative exon VASE 
in extracted RNA ofhuman granulosa cells. The use of oligonucleotide 
primers downstream and upstream the exon 7/8 splice junction in PCR 
amplification revealed that mainly human NCAM mRNA containing 
alternative exon, VASE, is present in freshly isolated granulosa cells 
(Iane 2) and granulosa cells cultured for I day (lane 3). This is indicated 
by the band of 337 bp. Non-VASE mRNAs (307 bp band) augmented 
during the culturing period (lane 4; 2 days in culture) until similar 
amounts of NCAM with and without VASE can be detected after 4 
days in culture, when cells had undergone luteinization (Iane 5). As size 
marker (indicated at the left side), Hpoll-digested pBR322 radioac-
tively labelIed at its 5' end under standard conditions was used. Lane 
I, control cDNA clone NI [5], which contains alternative exon VASE 
(indicated by the presence of a 337 bp band); lane 6, PCR control 
(H20). 
of rodent NCAM and human NCAM differ too much 
and thus can not be used in SI nuelease analysis of 
NCAM in human cells. 
The similarities of the molecular form of NCAM (en-
docrine NCAM-140; [2]) in the present study, the studies 
in the rat [14] and the bovine species [17] are evident. 
Based on the data of all these studies, NCAM-140 could 
be involved in cell-to-cell adhesion (granulosa cells in the 
growing folliele), as well as cell separation (antrum for-
mation). In most previous studies NCAM has been sug-
gested to playa role in the autoadhesion of NCAM-
bearing cells of the same kind via a homophilie binding, 
such as in the endocrine cells of the pancreatic islet, in 
the adenohypophysis, in adrenal cortex, adrenal medulla 
and in the testis [10,15]. In these cases the 'recognition 
site' ofNCAMs, which was identified as lying within the 
third Ig domain [8], may be modulated by alternative 
splicing of the neighbouring fourth Ig domain. It is con-
ceivable that altered NCAM forms could account for 
various degrees of cellular 'adhesiveness', and that the 
change in the amounts ofNCAM isoforms with or with-
out exon VASE, when granulosa cells undergo luteiniza-
tion, could affect NCAM function and cell behavior. 
Such a regulatory influence has been observed in neu-
rons, where VASE down-regulated the neurite out-
growth-promoting effect of NCAM [9,34]. 
Besides isoform switching (e.g. exelusion of the VASE 
exon), changes in the function of NCAM mayaIso be 
accomplished by post-translational changes (e.g. loss of 
polysialic acid modifications) [35,36]. Thus the alterna-
tively spliced exon VASE in the fourth Ig domain, which 
is physically elose enough to the regions of the moleeule 
thought to mediate cell-cell interaction, may modulate 
interaction of granulosa cells. In addition, soluble 
NCAM forms observed in different body fluids [37], pos-
211 
sibly ineluding the folliele fluid [14], could participate in 
the regulation of cell separation by saturating cell-bound 
NCAM. 
In conelusion, the present results showing that specific 
isoforms of the adhesion moleeule NCAM are expressed 
by human granulosa cells in vivo and by granulosa-Iutein 
cells in culture hint for the first time at the involvement 
ofNCAM in the processes offolliculogenesis and forma-
tion of the corpus luteum in the human ovary. Addi-
tional studies are required to pinpoint the precise roles 
and the regulation ofNCAM expression by ovarian cells, 
especially because now the question ofthe function(s) of 
NCAM in the developing folliele and in the corpus 
luteum have become of potential elinical relevance. 
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